Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model

References

• Katzmarzyk PT, Church TS, Craig CL, et al. Sitting time and mortality from all causes, cardiovascular disease, and cancer. Med Sci Sports Exerc. 2009;41:998–1005.
   PubMed Web of Science ®Google Scholar
• Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1–25.
   PubMed Web of Science ®Google Scholar
• Chait A, Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res. 2009;50:S335–S3S9.
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035–2038.
   PubMed Web of Science ®Google Scholar
• Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993. Diabetes Care. 1998;21:1138–1145.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–2581.
   PubMed Web of Science ®Google Scholar
• Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL the Strong Heart Study. Arterioscler Thromb Vasc Biol. 2000;20:830–835.
   PubMed Web of Science ®Google Scholar
• Asgary S, Solhpour A, Parkhideh S, et al. Effect of hydroalcoholic extract of hypericum perforatum on selected traditional and novel biochemical factors of cardiovascular diseases and atherosclerotic lesions in hypercholesterolemic rabbits: a comparison between the extract and lovastatin. J Pharm Bioall Sci. 2012;4:212.
   PubMedGoogle Scholar
• Bansal SK, Agarwal S, Daga MK. Conventional and advanced lipid parameters in premature coronary artery disease patients in India. J Clin Diagn Res. 2015;9:BC07–BC11.
   PubMed Web of Science ®Google Scholar
• Frostegård J, Nilsson J, Haegerstrand A, et al. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA. 1990;87:904–908.
   PubMed Web of Science ®Google Scholar
• Shi H, Mao X, Zhong Y, et al. Lanatoside C promotes foam cell formation and atherosclerosis. Sci Rep. 2016;6:20154.
   PubMed Web of Science ®Google Scholar
• Mehta JL, Sanada N, Hu CP, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res. 2007;100:1634–1642.
   PubMed Web of Science ®Google Scholar
• Zeibig S, Li Z, Wagner S, et al. Effect of the oxLDL binding protein Fc-CD68 on plaque extension and vulnerability in atherosclerosis. Circ Res. 2011;108:695–703.
   PubMed Web of Science ®Google Scholar
• Li L, Sawamura T, Renier G. Glucose enhances human macrophage LOX-1 expression role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res. 2004;94:892–901.
   PubMed Web of Science ®Google Scholar
• Farhangkhoee H, Khan Z, Barbin Y, et al. Glucose-induced up-regulation of CD36 mediates oxidative stress and microvascular endothelial cell dysfunction. Diabetologia. 2005;48:1401–1410.
   PubMed Web of Science ®Google Scholar
• Rezaei HB, Doosti M, Aminian M, et al. Compare the effect of eicosapentaenoic acid and oxidized low-density lipoprotein on the expression of CD36 and peroxisome proliferator-activated receptor gamma. Iran Biomed J. 2013;17:84–92.
   PubMedGoogle Scholar
• Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–2051.
   PubMed Web of Science ®Google Scholar
• Belton O, Fitzgerald DJ. Cyclooxygenase isoforms and atherosclerosis. ERM. 2003;5:1–18.
   Google Scholar
• Fosslien E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci. 2005;35:347–385.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Rehm B, Abhari RS, et al. Production of M2000 (β-d-mannuronic acid) and its therapeutic effect on experimental nephritis. Environ Toxicol Pharmacol. 2007;24:60–66.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Rehm B, Sotoude M, et al. Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis. Immunopharmacol Immuno-toxicol. 2007;29:49–61.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Cuzzocrea S, Rehm B, et al. M2000: a revolution in pharmacology. Med Sci Monit. 2005;11:PI53–PI63.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Matsuo H, Nakane S, et al. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immuno-pharmacol Immunotoxicol. 2005;27:255–265.
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Cuzzocrea S, Rehm B, et al. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. Scand J Immunol. 2005;61:435–441.
   PubMed Web of Science ®Google Scholar
• Fattahi MJ, Abdollahi M, Agha Mohammadi A, et al. Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol. 2015;37:535–540.
   PubMed Web of Science ®Google Scholar
• Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation. 2006;114:583–590.
   PubMed Web of Science ®Google Scholar
• Trpkovic A, Resanovic I, Stanimirovic J, et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci. 2015;52:70–85.
   PubMed Web of Science ®Google Scholar
• Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol. 2002;22:1162–1167.
   PubMed Web of Science ®Google Scholar
• Ganjifrockwala F, Joseph J, George G. Serum oxidized LDL levels in type 2 diabetic patients with retinopathy in Mthatha Region of the Eastern Cape Province of South Africa. Oxid Med Cell Longev. 2016;2016:2063103.
   PubMedGoogle Scholar
• Nickel T, Schmauss D, Hanssen H, et al. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis. 2009;205:442–450.
   PubMed Web of Science ®Google Scholar
• Lu H, Yao K, Huang D, et al. High glucose induces upregulation of scavenger receptors and promotes maturation of dendritic cells. Cardiovasc Diabetol. 2013;12:80.
   PubMed Web of Science ®Google Scholar
• Ye W, Li X, Xu C, et al. Effects of oxidized low-density lipoprotein on expression of type A scavenger receptor in human mesangial cells. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004;26:34–37.
   PubMedGoogle Scholar
• Handberg A, Levin K, Højlund K, et al. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma A novel marker of insulin resistance. Circulation. 2006;114:1169–1176.
   PubMed Web of Science ®Google Scholar
• Chen M, Nagase M, Fujita T, et al. Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and AGE. Biochem Biophys Res Commun. 2001;287:962–968.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Quehenberger O, Kondratenko N, et al. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol. 1998;18:794–802.
   PubMed Web of Science ®Google Scholar
• Mortazavi-Jahromi SS, Jamshidi MM, Farazmand A, et al. Pharmacological effects of β-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-κB gene expression, as target molecules in inflammatory reactions. Pharmacol Rep. 2017;69:479–484.
   PubMed Web of Science ®Google Scholar
• Fattahi MJ, Jamshidi AR, Mahmoudi M, et al. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: a 12-week randomized, placebo-controlled, phase I/II clinical trial. Int Immunopharmacol. 2018;54:112–117.
   PubMed Web of Science ®Google Scholar
• Roozbehkia M, Mahmoudi M, Aletaha S, et al. The potent suppressive effect of β-d-mannuronic acid (M2000) on molecular expression of the TLR/NF-kB Signaling Pathway in ankylosing spondylitis patients. Int Immunopharmacol. 2017;52:191–196.
   PubMed Web of Science ®Google Scholar
• Ahmadi H, Jamshidi AR, Mahmoudi M, et al. The potent inhibitory effect of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on anti-cyclic citrullinated peptide antibodies, rheumatoid factor and anti-dsDNA antibodies in patients with rheumatoid arthritis. Curr Drug Discov Technol. 2017;14:206–214.
   PubMedGoogle Scholar
• Ahmadi H, Jamshidi AR, Mahmoudi M, et al. Hematological improvement of patients with active rheumatoid arthritis by β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property. Iran J Allergy Asthma Immunol. 2017;16:433–442.
   PubMed Web of Science ®Google Scholar